There are new FDA guidelines for coronavirus vaccine developers.
Two months of follow-up data on volunteers in phase 3 trials are now needed before Emergency Use Authorization will be considered.
There are new FDA guidelines for coronavirus vaccine developers.
Two months of follow-up data on volunteers in phase 3 trials are now needed before Emergency Use Authorization will be considered.